

ENOCHIAN BIOSCIENCES TO PRESENT AT BIOTECH SHOWCASE 2019

LOS ANGELES, Calif. – November 23, 2018 – Enochian Biosciences, Inc. (“Enochian”) (OTCQB: ENOB), a biopharmaceutical company developing potentially curative and preventative gene-modified cell therapy platforms to transform the lives of persons living with HIV and cancer patients, today announced that the management team is scheduled present at the 2019 Biotech Showcase to be held on January 7-9, 2019 in San Francisco, CA.

Eric Liere, M.D., MBA, Chief Executive Officer, is scheduled to present on Monday, January 7, 2019 at 3:00 p.m. PST, Yosemite A (ballroom level). For more information, please visit the Company’s website at <https://enochianbio.com/>.

About Enochian

Enochian Biosciences is a biopharmaceutical company focused on the development and commercialization of novel gene-modified cell therapies aimed to change the course of treatment in HIV/AIDS and cancer. The Company utilizes its proprietary expertise in gene therapy, gene regulation and cell therapy to alter the course of multiple indications. The Company’s lead candidate, ENO-1001 (pre-IND) is a potential cure for HIV/AIDS. ENO-2001 is an HIV vaccine in preclinical stage, and its additional compounds ENO-5001 (gene-modified allogeneic dendritic cell therapy for solid cancers) and ENO-4002 (for prevention of relapse in colon cancer patients) are in discovery stages.

Contacts:

ICR Healthcare

Media:

James Heins

Tel: +1 203 682 8251

Email: James.Heins@icrinc.com

Investors:

Stephanie Carrington

Tel: +1 646 277 1282

Email: Stephanie.Carrington@icrinc.com